Media Report | Jacobio Pharma

9 press releases in total

2024

May 1, 2024

Glecirasib Demonstrates Encouraging Efficacy and Safety in KRASG12C-Mutated NSCLC in Phase 2 Trial From China
May 1, 2024

Phase 2 Study of Glecirasib Meets Primary End Point in KRAS G12C-Mutant NSCLC
Apr 8, 2024

Pharma Boardroom: Interview with Dr. Wang Yinxiang
Feb 20, 2024

Chinese inhibitor drug candidate becomes first to enter phase-3 clinical study

2023

Aug 10, 2023

Glecirasib Receives Breakthrough Therapy Designation in China for KRAS G12C–Mutated Pancreatic Cancer

2021

Jul 9, 2021

China Daily: Drugmakers increasingly looking abroad

2020

Dec 22, 2020

Bloomberg: Jacobio Pharmaceuticals CEO Dr. Wang Yinxiang on Hong Kong IPO
Dec 21, 2020

BioWorld: Jacobio launches $174M IPO in Hong Kong, advances SHP2 programs
Jun 1, 2020

Fierce Biotech: AbbVie pens cancer pact with U.S.-China biotech Jacobio